FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: NASDAQ:OXGN

Sort
E.g., 2013-05-23
E.g., 2013-05-23
Enter a comma separated list of user names.

KTOS, Kratos Defense & Security Solutions, Inc.

** On its third quarter fiscal 2011, KTOS posted revenues of $211.0 million, a 75.97% increase compared to revenues of $119.9 million in the same period a year ago. For the fourth quarter, KTOS is forecasting revenues to increase to approximately $230 to $240 million.

Amicus Therapeutics, Inc. (Nasdaq:FOLD) and GlaxoSmithKline (GSK) announced that the first patient has commenced dosing in a Phase 3 global registration study (Study 012) to compare the safety and efficacy of Amigal(TM) (migalastat HCl) and enzyme replacement therapy (ERT) for the treatment of Fabry disease.

Geron Corporation (NASDAQ:GERN) previously announced the publication of preclinical data demonstrating that the company’s telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, targets cancer stem cells from multiple myeloma, pancreatic and breast cancers.

Pages

ADVERTISE WITH US